TY - JOUR
T1 - Restoring chemotherapy and hormonetherapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
AU - Shanmugam, Rajasubramaniam
AU - Jayaprakasan, Vetrichelvan
AU - Gokmen-Polar, Yesim
AU - Kelich, Stephanie
AU - Miller, Kathy D.
AU - Yip-Schneider, Michele
AU - Cheng, Liang
AU - Bhat-Nakshatri, Poornima
AU - Sledge, George W.
AU - Nakshatri, Harikrishna
AU - Zheng, Qi Huang
AU - Miller, Michael A.
AU - DeGrado, Timothy
AU - Hutchins, Gary D.
AU - Sweeney, Christopher J.
PY - 2006/10/1
Y1 - 2006/10/1
N2 - BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.
AB - BACKGROUND. Nuclear Factor kappa B (NFκB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P). METHODS. The in vitro effects of P were assessed using the androgen independent cell line, CWR22Rv1, and human umbilical endothelial cells (HUVECs). The in vivo activity of P as a single agent and its ability to augment the efficacy of docetaxel and the anti-androgen, bicalutamide, were determined using the CWR22Rv1 xenograft model. RESULTS. Parthenolide at low micromolar concentration inhibited proliferation of CWR22Rv1 and HUVEC cells, promoted apoptosis and abrogated NFκB-DNA binding. Parthenolide downregulated anti-apoptotic genes under NFκB control, TRAF 1 and 2, and promoted sustained activation of c-jun-NH2 kinase (JNK). Parthenolide also augmented the in vivo efficacy of docetaxel and restored sensitivity to anti-androgen therapy. CONCLUSION. These studies demonstrate parthenolide's anti-tumor and anti-angiogenic activity, and its potential to augment the efficacy of chemotherapy and hormonal therapy.
KW - Angiogenesis
KW - Anti-tumor
KW - NFκB
KW - Parthenolide
UR - http://www.scopus.com/inward/record.url?scp=33749068887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749068887&partnerID=8YFLogxK
U2 - 10.1002/pros.20482
DO - 10.1002/pros.20482
M3 - Article
C2 - 16921510
AN - SCOPUS:33749068887
SN - 0270-4137
VL - 66
SP - 1498
EP - 1511
JO - Prostate
JF - Prostate
IS - 14
ER -